NPC is a cancerous tumor that originates from the nasopharynx and has a high incidence in East and Southeast Asia. Concurrent cisplatin-radiotherapy has long been standard treatment, but the toxicity of cisplatin, especially nausea, vomiting, and renal damage, usually constrains tolerability and impairs patients' quality of life. This new phase 3 trial offers solid evidence that a cisplatin-sparing strategy can be as effective and safer.
This multicenter, open-label, randomized phase 3 clinical trial was carried out in 13 Chinese hospitals from August 2021 to July 2022.
Randomization:
Standard therapy group (n=266): toripalimab + gemcitabine-cisplatin induction chemotherapy + concurrent cisplatin-radiotherapy
Cisplatin-sparing group (n=266): same regimen without concurrent cisplatin
Toripalimab (240 mg) was administered every 3 weeks for a total of 17 cycles (3 induction, 3 concurrent with radiotherapy, and 11 adjuvant).
The coprimary outcomes were failure-free survival (noninferiority margin: 8%) and all-grade incidence of vomiting. Secondary outcomes were overall survival, recurrence-free survival, distant metastasis–free survival, safety, tumor response, quality of life, and tolerability.
Key Findings
With a median follow-up of 37 months (range, 4–50 months):
Failure-free survival (3-year rate):
Cisplatin-sparing group: 88.3%
Standard therapy group: 87.6%
Difference: 0.7% (1-sided 95% CI lower limit, −3.9%)
P = .002 for noninferiority (HR, 0.92; 95% CI, 0.66–1.79; log-rank P = 0.73)
Incidence of all-grade vomiting:
Cisplatin-sparing group: 26.2% (68/260)
Standard therapy group: 59.8% (156/261)
Difference: 33.6% (P < .001)
Quality of life:
Improved in cisplatin-sparing group, particularly in gastrointestinal symptoms, global health status, and functional scores
Patient-reported participation rates: 87.5% (QoL) and 94.7% (tolerability)
Overall survival and recurrence-free outcomes: Similar between groups
In this large phase 3 trial, toripalimab combined with induction chemotherapy and radiotherapy was found to be noninferior on survival outcomes and superior on safety and quality of life for advanced NPC. These results indicate that a cisplatin-sparing regimen could be a new standard of care, minimizing treatment burden without loss of efficacy.
Reference:
The DIAMOND Study Group. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. Published online August 21, 2025. doi:10.1001/jama.2025.13205
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.